Clinical Trial

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

Study acronym: RIFA-SNAP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT07253688
Lead Sponsor Todd C. Lee MD MPH FIDSA
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR), University of Melbourne, The Peter Doherty Institute for Infection and Immunity
Conditions Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis
Enrollment 330 participants
Start Date 2025-11-10
Primary Completion 2029-12 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-10